Double-blind randomized trial of progesterone to prevent preterm birth in second-trimester bleeding
Raed Salim, Marwan Hakim, Noah Zafran, Zohar Nachum, Shabtai Romano, Gali Garmi, Raed Salim, Marwan Hakim, Noah Zafran, Zohar Nachum, Shabtai Romano, Gali Garmi
Abstract
Introduction: Second-trimester vaginal bleeding increases the risk of spontaneous preterm birth. We aimed to examine the efficacy of vaginal progesterone to reduce preterm birth rate in women with second-trimester vaginal bleeding.
Material and methods: Two-center, double-blind, placebo-controlled trial involving pregnant women with second-trimester vaginal bleeding. Women with documented uterine bleeding were randomly assigned in a 1:1 ratio to receive 200 mg of micronized vaginal progesterone or placebo once daily at 16-26 weeks until 36 weeks of gestation. Women who had prior preterm birth or short cervix diagnosed before recruitment were not eligible. The primary outcome was spontaneous delivery <37 weeks.
Clinical trial registration: clinicaltrials.gov Identifier: NCT01269450.
Results: Between March 2011 and January 2017, 128 women gave consent and were randomized; 16 withdrew consent and 3 had a second-trimester termination of pregnancy. The final analysis included 109 women: 60 in the progesterone group and 49 in the placebo group. Demographic and obstetric characteristics did not differ between the groups. Primary outcome occurred in 19 (31.7%) and 12 (24.5%) in the progesterone and placebo groups, respectively (odds ratio [OR] 1.32; 95% confidence interval [CI] 0.55-3.16; P = 0.53). The proportion of births <34 weeks was similar between the groups (OR 1.19; 95% CI 0.47-3.02; P = 0.72), as were the survival curves from randomization to delivery (hazard ratio, 1.24; 95% CI, 0.60-2.56; P = 0.57). There were no significant differences in neonatal morbidities between the groups. The study was ended prematurely because of slow recruitment.
Conclusions: Antepartum vaginal progesterone does not seem to reduce the incidence of preterm birth in women with second-trimester bleeding.
Keywords: preterm birth; second-trimester bleeding; vaginal progesterone.
© 2019 Nordic Federation of Societies of Obstetrics and Gynecology.
References
REFERENCES
- Society for Maternal Fetal Medicine Publications Committee. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol. 2008;112:963-965.
- Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379-2385.
- Romero R, Nicolaides KH, Conde-Agudelo A, et al. Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol. 2016;48:308-317.
- Saccone G, Schoen C, Franasiak JM, Scott RT Jr, Berghella V. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2017;107:430-438.
- Norman JE, Marlow N, Messow CM, et al.; OPPTIMUM Study Group. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016;387:2106-2116.
- Axelsen SM, Henriksen TB, Hedegaard M, Secher NJ. Characteristics of vaginal bleeding during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1995;63:131-1314.
- Sipila P, Hartikainen-Sorri A. Perinatal outcome of pregnancies complicated by vaginal bleeding. Br J Obstet Gynecol. 1992;99:959-963.
- Parant O, Clouet-Delannoy M, Connan L, Duclusaud A, Chale J, Fournié A. Metrorrhagia during the second trimester of pregnancy: obstetrical and perinatal outcome. A retrospective study including 85 cases. J Gynecol Obstet Biol Reprod (Paris). 2000;29:66-72.
- Koifman A, Levy A, Zaulan Y, et al. The clinical significance of bleeding during the second trimester of pregnancy. Arch Gynecol Obstet. 2008;278:47-51.
- Elovitz MA, Baron J, Phillippe M. The role of thrombin in preterm parturition. Am J Obstet Gynecol. 2001;185:1059-1063.
- Rosen T, Kuczynski E, O'Neill LM, Funai EF, Lockwood CJ. Plasma levels of thrombin-antithrombin complexes predict preterm premature rupture of the fetal membranes. J Matern Fetal Med. 2001;10:297-300.
- Cakmak H, Schatz F, Huang ST, et al. Progestin suppresses thrombin- and interleukin-1β-induced interleukin-11 production in term decidual cells: implications for preterm delivery. J Clin Endocrinol Metab. 2005;90:5279-5286.
- Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
- Tooher RL, Middleton PF, Crowther CA. A thematic analysis of factors influencing recruitment to maternal and perinatal trials. BMC Pregnancy Childbirth. 2008;8:36.
- Watson J, Torgerson D. Increasing recruitment to randomised trials: a review of randomised controlled trials. BMC Med Res Methodol. 2006;6:34.
- Committee on Practice Bulletins-Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol. 2012;120:964-973.
- Society for Maternal-Fetal Medicine (SMFM) Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Am J Obstet Gynecol. 2017;216:B11-B13.
- Signore CC, Sood AK, Richards DS. Second-trimester vaginal bleeding: correlation of ultrasonographic findings with perinatal outcome. Am J Obstet Gynecol. 1998;178:336-340.
- Hammouda A. Bleeding in the first two trimesters of pregnancy. Review of 1000 cases. Int Surg. 1966;45:447-449.
- Scott J. Vaginal bleeding in the midtrimester of pregnancy. Am J Obstet Gynecol. 1972;113:329-334.
- Chan CC, To WW. Antepartum hemorrhage of unknown origin-what is its clinical significance? Acta Obstet Gynecol Scand. 1999;78:186-190.
- Gabbe SG, Niebyl JR, Simpson JL, eds. Antepartum and Postpartum Hemorrhage. 7th ed. St. Louis: CV Mosby; 1983:403.
- Lockwood C, Kuczynski E. Markers of risk for preterm delivery. J Perinat Med. 1999;27:5-20.
- Elovitz MA, Baron J, Phillippe M. The role of thrombin in preterm parturition. Transactions of the Twenty-First Annual Meeting of the Society for Maternal-Fetal Medicine. Am J Obstet Gynecol. 2001;185:1059-1063.
- Buhimschi CS, Schatz F, Krikun G, Buhimschi IA, Lockwood CJ. Novel insights into molecular mechanisms of abruption-induced preterm birth. Expert Rev Mol Med. 2010;12:e35.
- Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev. 2009;23:167.
- Lockwood CJ, Kayisli UA, Stocco C, et al. Abruption-induced preterm delivery is associated with thrombin-mediated functional progesterone withdrawal in decidual cells. Am J Pathol. 2012;181:2138.
Source: PubMed